Publication | Closed Access

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

UrologyOncologyGenitourinary CancerMedicineClinical TrialsStandard Antiandrogen TherapyPharmacotherapyProstatic DiseasePharmacologyEndocrine-related Cancer